Today's Rundown Rakuten Medical reels in another megaround to fund cancer R&D Phase 3 trial of Transgene's oncolytic virus halted for futility BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end Freezing your T cells today for potential CAR-T therapies tomorrow EuroBiotech Report—R&D execs leave Adaptimmune and Zealand, Wellington fund, Gilead and Woodford FiercePharmaAsia—Takeda's cost-saving progress; Dr. Reddy's shortfall; Strides' China JV Chutes & Ladders—Mylan CEO Bresch to exit company after Upjohn merger Featured Story | | | Friday, August 2, 2019 Rakuten Medical has raised $100 million to advance its pipeline of photoimmunotherapy oncology prospects. The biotech hopes to use antibodies and light to destroy cancer cells while leaving healthy tissues unharmed. |
|
|
Top Stories Friday, August 2, 2019 A phase 3 liver cancer trial of Transgene and SillaJen’s oncolytic virus has been stopped early for futility. The setback sent the share prices of the companies downward and added to doubts about the effectiveness of oncolytic viruses. Friday, August 2, 2019 In its race to be the first to submit a gene therapy for review in hemophilia, BioMarin is dropping development of a lower dose of its valrox treatment, amid plans to get its applications into the hands of regulators before the end of the year. Thursday, August 1, 2019 A company offering to freeze donors’ T cells and save them until the day they are needed—perhaps even years before the onset of cancer or disease—is getting off the ground with $1 million in funding. Thursday, August 1, 2019 In this week's EuroBiotech Report, Adaptimmune, Zealand suffer senior R&D departures, Wellington raises fund and Gilead talks up Galapagos deal. Friday, August 2, 2019 Takeda is making progress on its cost-saving plans. The U.S. FDA cited Dr. Reddy's for manufacturing shortfalls in a Form 483. Following its Indian pharma peers, Strides Pharma entered China through a JV with Sihuan Pharma. And more. Friday, August 2, 2019 Mylan CEO Bresch set to retire after merger with Pfizer spinoff Upjohn; Adaptimmune CSO leaving to "pursue other opportunities"; Verastem pegs Stuglik as next head honcho. Resources Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Cambrex The highest number of NCEs approved by the FDA…the fastest growing small molecule clinical pipeline reported in 20 years…these are exciting times for our industry. Sponsored by: Reprints Desk, Inc. Cut your research time in half - with an easy-to-use app for scientists that combines full-featured reference management with integrated search and on-demand document delivery. Sponsored by: Almac Group Innovative Just in Time Manufacturing solution enables sponsors full late stage customisation of clinical trial materials Sponsored by: PwC How are employer activism strategies beginning to replace the cost-sharing of the past, and improve the health of the workforce? Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Veradigm Patient demand for more information on their care is driving new e-prescribing regulations, and technology is evolving to help providers meet them. This report provides an overview of key areas where such regulation has emerged, and what it could mean for providers and healthcare IT companies. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 